Peter Attia· MD
two to four milligrams was a very common daily dose for rap immune and again this is rad001 so it's a different vehicle but it's comparable and so 0.5 daily would definitely be lower than what i was used to seeing people get
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
two to four milligrams was a very common daily dose for rap immune and again this is rad001 so it's a different vehicle but it's comparable and so 0.5 daily would definitely be lower than what i was used to seeing people get
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
The "high risk" framing here is the right call. I've had three patients ask about rapa this month and none of them grasped the immunosuppression tradeoff until I walked them through it.
The PEARL trial framing in the dossier is the clearest writeup I've seen for a non-specialist. Worth linking from the AMA pages too.
I'm on 6mg/week, year two. Tracking IL-6, fasting glucose, lipids. Happy to share the spreadsheet if Whalespan wants longitudinal user data.
The dosing variance across the advocate camp is staggering. 3mg, 5mg, 8mg, biweekly, weekly… brief is right that "monitor or specialist only" is the responsible read.
so it's a clever design because the five and the twenty that are both getting it once a week gives you a great you get to answer both efficacy and toxicity questions as they pertain to that dose the 0.5 daily versus the five weekly is your closest aggregate dose where you get to see is there a difference in trough so overall a lot of interesting stuff
if your rapamycin dose is somewhere between two and eight milligrams a day roughly at the immunosuppression level of dosing which is what we're talking about that's comparable to five to ten milligrams of red zero zero one
Rapamycin extends median and maximum lifespan in mice across multiple lab strains and dosing protocols.
Rapamycin will extend human lifespan by 5+ years at standard weekly dosing.
Weekly rapamycin dosing in healthy adults shows favorable safety and immune markers in early observational data.
Chronic low-dose rapamycin imposes an immune trade-off that outweighs the longevity hypothesis for most healthy adults.
mTORC1 inhibition is the mechanistic backbone for rapamycin's healthspan effects in mammals.
The PEARL trial showed an acceptable 48-week safety profile in healthy adults on weekly rapamycin.